No Data
No Data
Cystic Fibrosis Market Is Projected to Boost by 2034, Predicts DelveInsight | Key Companies - Verona Pharmaceuticals, Vertex Pharmaceuticals, Krystal Biotech, Aridis Pharmaceuticals, BiomX, Inc., Boehringer Ingelheim
New York, USA, July 11, 2024 (GLOBE NEWSWIRE) -- Cystic Fibrosis Market is Projected to Boost by 2034, Predicts DelveInsight | Key Companies - Verona Pharmaceuticals, Vertex Pharmaceuticals, Krystal Biotech,
Express News | Aridis- in Discussions With Other Pharmaceutical Cos and Investment Firms on Possible Partnerships and Investments on Its Apex Platform Technology
Express News | Aridis - in Discussions With Pharmaceutical Cos,Investment Firms on Possible Partnerships on Its Clinical Product Candidates Ar- 301, Ar-320, Ar-501
Express News | Aridis Provides Corporate Update
Aridis Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders Until January 12, 2024
Aridis Pharmaceuticals, Inc. (OTC QB: ARDS) today announced that its 2023 Annual Meeting of Stockholders ("Annual Meeting"), scheduled for Friday, December 15, 2023, was convened and adjourned, without any business being conducted, due to lack of the requisite quorum.
HC Wainwright & Co. Reiterates Buy on Aridis Pharmaceuticals, Maintains $2 Price Target
HC Wainwright & Co. analyst Vernon Bernardino reiterates Aridis Pharmaceuticals (OTC:ARDS) with a Buy and maintains $2 price target.
No Data